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assessment: does reducing the number of lesions
impact response assessment in melanoma patients
treated with ipilimumab?
Mizuki Nishino1*, Maria Gargano2, Margaret Suda2, Nikhil H Ramaiya1† and F Stephen Hodi2†Abstract
Background: Investigate the impact of the reduction of the number of target lesions on immune-related response
assessment in advanced melanoma patients treated with ipilimumab.
Method: Ninety patients (53 males, 37 females; age range: 25–87) with advanced melanoma treated with ipilimumab
in two clinical trials were studied. Tumor measurements during trial allowing up to 5 lesions per organ and 10 lesions
in total were retrospectively reviewed. A second set of tumor measurements allowing up to 2 lesions per organ and 5
lesions in total was generated. Immune-related response assessments by two measurements were compared.
Results: The number of target lesions was significantly reduced when up to 2 per organ and 5 in total lesions were
allowed (Wilcoxon P < 0.0001). The immune-related response assessment using reduced number of lesions was highly
concordant with assessment using the original number of lesions (Spearman r for the percent change on 1st-3rd
follow-up: 0.860-0.970; κw for best immune-related response: 0.908). Median time-to-progression was 26.9 months
(95%CI: 9.1-∞) by both assessments. Interobserver agreement of measurements was high for both assessments,
with the concordance correlation coefficient above 0.98.
Conclusion: Reduction of the number of target lesions did not significantly affect immune-related response
assessment or the measurement variability in advanced melanoma patients treated with ipilimumab. Using up to 2
per organ and 5 in total target lesions is proposed to assess immune-related response, while it is important to keep
other novel features of immune-related response criteria such as confirmation of progression and inclusion of new
lesion measurements.
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Anti-cancer immunotherapeutic agents have shown prom-
ising results in treatment of advanced cancer patients, as
represented by survival benefit of ipilimumab in advanced
melanoma patients [1-4]. Because of the distinct biologic
mechanisms of anti-cancer activity of immunotherapeutic
agents, cancer patients treated with immunotherapy need
to be evaluated with special attention to the characteristics* Correspondence: Mizuki_Nishino@dfci.harvard.edu
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unless otherwise stated.of immune-related tumor response. The immune related
response criteria (irRC) has been developed to adequately
characterize additional patterns of response and progres-
sion specific to patients treated with immunotherapy, that
cannot be captured by the conventional criteria such as
such as Response Evaluation Criteria in Solid Tumors
(RECIST) [5,6]. The irRC has been increasingly recognized
as one of the novel criteria to complement limitations of
RECIST in patients treated with novel anti-cancer agents
[5,6]. The irRC was recently used in a phase 2 clinical trial
of ipilimumab in lung cancer patients to assess response
and define trial endpoints [7].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sponse criteria using one-dimensional, longest diameters
as in RECIST with the original irRC utilizing bidimensional
measurements in advanced melanoma patients treated with
ipilimumab. Unidimensional immune-related response
assessment was highly concordant with bidimensional
assessment, with better measurement reproducibility [8].
The use of the unidimensional measurements can be
proposed, in order to reliably assess immune-related
tumor response and provide results that can be directly
compared to the results of trials based on unidimen-
sional, RECIST-based assessment in the past decade.
RECIST, originally described in 2000, is the most com-
monly utilized criteria to assess tumor response to therapy
in solid tumors, and is widely applied in clinical trials to
determine endpoints, providing a basis for the approval of
anti-cancer agents by Food and Drug Administration
(FDA). The RECIST working group published a revised
RECIST guideline (RECIST1.1) in January 2009, which has
also been widely accepted and utilized to assess response
and define progression in oncologic clinical trials [9-11].
One of the major changes of RECIST1.1 compared to the
original RECIST (RECIST1.0) was the reduction of the
number of target lesions, from 5 to 2 per organ, and from
10 to 5 in total. In our previous studies assessing the
impact of RECIST1.1 guideline in response assessment
of advanced non-small-cell lung patients, response assess-
ment by RECIST1.1 was highly concordant with that by
RECIST1.0 with improved reproducibility and required
less time for measurements [12,13]. Other studies also
described similar results in assessment of lung cancer
and colon cancer, demonstrating the concordance of
response assessment with decreased number of target
lesions [14,15].
During the review of prospective tumor measurement
records in our previous study comparing bidimensional
versus unidimensional immune-related response assess-
ment, it was noted that patients with advanced melanoma
have multiple target lesions located in various organs and
sites, not only in the visceral organs but also in the skin
and muscles. The number of target lesions and the distri-
bution of lesions in melanoma patients seemed distinct
from previously studied cohorts such as patients with lung
cancer or colon cancer. Given these observations, it was
deemed worthwhile to study the immune-related response
assessment by limiting the number of target lesions as
defined in RECIST1.1, and compare the results with the
assessment using the original number of target lesions.
The purpose of the present study was to evaluate the
impact of the reduction of the number of target lesions
in immune-related response assessment in advanced
melanoma patients treated with ipilimumab. Given the
results of our previous study comparing bidimensional ver-
sus unidimensional immune-related response assessment,unidimensional measurements were used for the purpose
of the present study. We hypothesized that reducing the
number of target lesions does not significantly affect the
results of immune-related response assessment. We also
evaluated the interobserver variability of measurements to
assess the impact of the reduction of the number of target
lesions on measurement variability.
Results and discussion
The number of target lesions and baseline measurements
in 90 patients
The number of target lesions by irRC simulating
RECIST1.1 was significantly smaller than that by irRC
simulating RECIST1.0 (median number of target lesions
per patient: 3 versus 4, respectively, P < 0.0001; total num-
ber of lesions in the cohort: 275 versus 381). The number
of target lesions decreased in 50 of 90 patients (56%) when
irRC simulating RECIST1.1 was used (median number of
reduced target lesions: 1, range: 1–5) (Figure 1). The rea-
sons of reduction of target lesions were a) reduction of
maximum number of lesions per organ in 14 patients, b)
criteria for measurable lymph nodes in 11 patients, c)
reduction of maximum number of lesions in total in 7
patients, and d) combination of 2 or 3 of these reasons
in 18 patients. One patient with one target lesion by
irRC simulating RECIST1.0 had no target lesion when
irRC simulating RECIST1.1 was used, because the lesion
was a lymph node <15 mm in short axis.
Baseline measurements by two criteria demonstrated a
significant correlation, with a Spearman correlation coeffi-
cient of 0.951 (95% CI: 0.93-0.97) (Figure 2). The baseline
measurements by irRC simulating RECIST1.1 was signifi-
cantly smaller than that by irRC simulating RECIST1.0
(median: 9.0 versus 12.0 cm, respectively, P < 0.0001).
Response assessment during immunotherapy by
two criteria
Response assessment was performed in 71 patients who
had at least one follow-up CT during therapy among the
90 patients. Figure 3 demonstrates the percent changes
of the measurements by two criteria at each follow-up
scan (from 1st to 17th follow-up). High concordance
was noted between the percent changes by two criteria,
with Spearman correlation coefficient of 0.970 (95%
CI: 0.95-0.98) for the first follow-up (n = 71), 0.946
(95% CI: 0.90-0.97) for the 2nd follow-up (n = 43), 0.860
(95% CI: 0.71-0.94) for the 3rd follow-up (n = 27). Figure 4
represents the waterfall plot of the percent changes by
two criteria at the 1st follow-up in 71 patients. Response
assessment based on the percent changes of measure-
ments by two criteria on the 1st-3rd follow-up had almost
perfect agreement, with κw of 0.913 (95% CI: 0.84-0.99)
for the 1st, 0.901 (95% CI: 0.82-0.98) for the 2nd, and 0.837
(95% CI: 0.65-1.0) for the 3rd follow-up. Best immune
Figure 1 The waterfall plot represents a number of target lesions for each patient using irRC simulating RECIST1.0 (dark gray bars)
and irRC simulating RECIST1.1 (light gray bars). The number of target lesions by irRC simulating RECIST1.1 was significantly smaller than that
by irRC simulating RECIST1.0 (P < 0.0001).
Nishino et al. Journal for ImmunoTherapy of Cancer 2014, 2:17 Page 3 of 12
http://www.immunotherapyofcancer.org/content/2/1/17related response by two criteria demonstrated almost
perfect agreement, with κw of 0.908 (95%CI: 0.82-0.99)
(Table 1). Time to progression (TTP) had a median of
26.9 months (95% CI: 9.1-∞) by both criteria. Given the
identical median TTP and its 95% confidence interval,Figure 2 The scatter plot represents the baseline measurements using
significant correlation was observed between baseline measurements using tthere was no evidence of a difference in TTP by two
criteria (Figure 5).
In order to address the impact of irRC in tumor response
assessment compared to the conventional assessment,
the comparison was also made between the responseirRC simulating RECIST1.0 and irRC simulating RECIST1.1. A
wo criteria (Spearman correlation coefficient, 0.951 [95% CI: 0.93-0.97]).
Figure 3 The percent changes of measurements using irRC simulating RECIST1.0 and irRC simulating RECIST1.1 at each follow-up from
the 1st to the 17th follow-up scans are shown. Dashed lines at +20% and −30% represent the cut-off values for progressive disease and partial
response, respectively. The observations within the lower left, middle center, and upper right boxes have concordant assessment between
tow measurements, while observations in other boxes have discordant assessment. One concordant observation (+80% by irRC simulating
RECIST1.0, +330% irRC simulating RECIST1.1) is not displayed since it is beyond the range of the Y axis.). The percent changes presented in
the figure are in comparison with baseline measurements when tumors are decreasing to assess response, and in comparison with the nadir
(the smallest measurement since baseline) when tumors are increasing to assess progression. These values are displayed since they are used
to define response/progression in patients at the time of response assessment. Please also note that the number of patients decreases as
the follow-up proceeds, starting from 71 patients at 1st follow-up, 43 patients at the 2nd follow-up, 27 patients at the 3rd follow-up, and so
on. There were 3 patients at the 12th -14th follow-up, 2 patients at 15th and 16th follow-up, and one follow-up at the 17th follow-up.
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ment by the conventional RECIST1.1, which does not
require confirmation of PD and defines PD at the time of
appearance of a new lesion (rather than including the new
lesion measurements in the tumor burden). TTP using
the conventional RECIST1.1 was much shorter, with a
median of 3.7 mos (95% CI: 2.7-5.3), compared to 26.9
mos using irRC simulating RECIST1.1 (Figure 6).
New lesions
New measurable lesions were noted in 9 patients (number
of new lesions: 4 in one, 2 in one, and 1 in seven patients,
using irRC simulating RECIST1.0). In one patient with 4
new lesions by irRC simulating RECIST1.0, only 2 of the 4
new lesions were allowed by irRC simulating RECIST1.1
since all 4 lesions were peritoneal lesions. In a patient with
one new lesion by irRC simulating RECIST1.0, the lesion
did not qualify to be a measurable new lesion because
it was a lymph node <15 mm in short axis. In another
patient with one new lesion by both criteria, the lesion
was a lymph node ≥15 mm in short axis, therefore, the
measurement of the new lesion added to the sum was
different between two criteria (the longest diameterversus short axis). For the remaining 6 patients, the
number or the measurements of new lesions did not
differ between the two criteria.
Measurement variability
In randomly selected 30 patients, the concordance cor-
relation coefficients (CCCs) between the measurements
performed during the trial and the measurements by the
radiologist performed in this study were 0.992 (95% CI:
0.98-0.99) for irRC simulating RECIST1.0, and 0.988
(95% CI: 0.98-0.99) for irRC simulating RECIST1.1. Figure 7
demonstrate Bland-Altman plots with 95% limits of
agreement and the average relative difference. The 95%
limits of agreement was (−23.0%, 14.1%) for irRC simulat-
ing RECIST1.0, and (−21.8%, 16.1%) for irRC simulating
RECIST1.1.
Discussion
The present study demonstrated that the immune-related
response assessment using decreased number of target
lesions simulating RECIST1.1 can provide highly con-
cordant results compared to the assessment using the ori-
ginal number of target lesions according to RECIST1.0.
Figure 4 The waterfall plot demonstrates the percent change of measurements by two criteria at the first follow-up scan. Dark gray
bars represent the percent changes by irRC simulating RECIST1.0, and light gray bars represent the percent changes by irRC simulating RECIST1.1.
Dashed lines at +20% and −30% represent the cut-off values for progressive disease and partial response, respectively. 5 patients with discordant
assessment are marked with asterisks (*).
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two assessments. Based on the results, the number of
target lesions in immune-related response assessment
can be reduced to up to 2 per organ and up to 5 in total
as defined in RECIST1.1, without significant changes
in response assessment results and reproducibility of
measurements.
Significant reduction of the number of target lesions
were noted when irRC simulating RECIST1.1 was used,
resulting in the reduction of the number of lesions in
56% of the patients. The result was expected since irRC
simulating RECIST1.1 allows only up to 2 lesions per
organ and up to 5 lesions in total, while irRC simulatingTable 1 Best overall response assessment by irRC
simulating RECIST1.0 and irRC simulatin RECIST1.1 in 71





irCR irPR irSD irPD
irCR 1 1 0 0 1
irPR 0 8 1 0 10
irSD 0 0 52 1 53
irPD 0 0 1 6 7
1 9 54 7 71
κw = 0.908 (95% CI: 0.82-0.99).RECIST1.0 allows up to 5 lesions per organ and 10 lesions
in total, and advanced melanoma patients often had more
than 2 lesions per organ and sometimes more than 5 le-
sions in total. The larger lesions based on unidimensional
measurements remained as target lesions when the number
of lesions exceeded the limit, since larger lesions were
considered to represent tumor burden during the course
of therapy. We also applied the revised criteria for meas-
urability of lymph node (≥15 mm in short axis) as defined
in RECIST1.1, which resulted in a reduction of the
number of target lesions in a total of 21 patients (as a
sole reason in 11 patients and in combination with
other reasons in 10 patients). The revised lymph node
guideline also resulted in a loss of target lesion in one
patient whose only measurable lesion was a lymph
node <15 mm in short axis, indicating the guideline can
affect the trial eligibility of patients since many trials
require at least one measurable lesion for enrollment, and
further studies are needed to address this important clin-
ical issue. The observation is concordant with the results
in other studies comparing RECIST1.0 and RECIST1.1 in
other solid tumors such as lung cancer and prostate
cancer [16]. It has been shown that RECIST1.1 with
decreased number of lesions requires significantly less
time compared to RECIST1.0, which will to lead time
saving and workflow in clinical practice [13].
The percent changes of measurements at each follow-up
were highly concordant between the two criteria, and the
Figure 5 Time to progression by irRC simulating RECIST1.1 and irRC simulating RECIST1.0 had a median survival of 26.9 months
(95% CI: 9.1-∞), without evidence of difference.
Figure 6 Time to progression by irRC simulating RECIST1.1 was much longer compared to that by conventional RECIST1.1 with median
TTP of 3.7 mos (95% CI: 2.7-5.3).
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Figure 7 Bland-Altman plots demonstrate the interobserver variability of measurements by irRC simulating RECIST1.0 (A), and by irRC
simulating RECIST1.1 (B), on baseline scans in randomly selected 30 patients. The 95% limits of agreement of measurements by irRC
simulating RECIST1.0 were (-23.0%, 14.1%; Figure 7A, dashed lines), while the 95% limits of agreement of measurements by irRC simulating
RECIST1.1 were (-21.8%, 16.1%; Figure 7B, dashed lines). The dotted lines represent the mean relative difference (%).
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studies had almost perfect agreement, with the weighted
kappa value >0.837, in spite of the significant reduction of
the number of target lesions by irRC simulating RECIST1.1.
The best immune-related response was also highly con-
cordant between the two criteria, with weighted kappa
value of 0.908. These results were concordant with our
hypothesis, that reducing the number of target lesions
does not significantly affect the results of immune-related
response assessment. The results were also quite simi-
lar to the previous studies comparing RECIST1.0 andRECIST1.1 in advanced lung cancer patients [12-14]. In a
study from our group evaluating RECIST1.0 and 1.1 in ad-
vanced NSCLC patients treated with erlotinib, the response
assessment results were highly concordant between the two
criteria with weighted κ of 0.905, while the number of tar-
get lesions was significantly reduced by RECIST1.1 [12].
Similar observation was also noted in the genomically de-
fined cohort of NSCLC patients with sensitizing EGFR
mutations treated with EGFR inhibitors, which demon-
strated measurements using RECIST1.1 require less time
compared to measurements using RECIST1.0 [13].
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TTP and its 95% CI, further supporting our hypothesis. The
result of TTP is concordant with the prior study of NSCLC
patients, which demonstrated no significant difference in
TTP by RECIST1.0 and RECIST1.1 [12]. Confirmation by 2
consecutive studies was required for both criteria, since this
was one of the most important feature of the original irRC
to differentiate initial apparent increase of tumor due to
accumulation of immune cells from true progression.
The cut off values to define response and progression
were −30% and +20% as defined by RECIST1.0 and 1.1,
because the assessments in the present study were based
on unidimensional measurements. Although the original
irRC published in 2009 used bidimensional measurements
based on WHO criteria, we chose to utilize unidimen-
sional, longest diameter measurements in this study. This
was because 1) the longest diameter measurements based
on RECIST were used in assessing response and defining
trial endpoints in the majority of the clinical trials of solid
tumors in the past decade, and 2) our previous study
demonstrated that unidimensional measurements provide
immune-related response assessment which is highly con-
cordant with the assessment using bidimensional mea-
surements with better reproducibility [8]. TTP using irRC
simulating RECIST1.1 was much longer compared to TTP
using the conventional RECIST; this is because 1) the
requirement of confirmatory observation for PD by irRC
allows patients to continue therapy beyond initial increase
of tumor burden without being assessed as having “pro-
gression” immediately at the first scan showing ≥20%
increase, and 2) new lesions by irRC does not define PD
(and instead their measurements are included in the sum
of the tumor burden) and therefore patients may continue
therapy without being labelled as “progressors” even in
the presence of new lesions. The results are indicative of
the impact of these 2 unique features of irRC on assessing
response and defining trial endpoints, which should be
kept in mind when designing trials of immunotherapeutic
agents and defining trial endpoints, and advocate the need
for future studies.
Particular attention was paid in the study design as to
the assessment of new lesions and their measurements.
The irRC simulating RECIST1.0 allows up to 5 new
lesions per organ and up to 10 new lesions, while irRC
simulating RECIST1.1 allows up to 2 new lesions per
organ and up to 5 new lesions in total; this is regardless
of the number of target lesions at baseline. Both cri-
teria included the measurements of new lesions in the
sum of the measurements to define response and pro-
gression, since this was one of the major features of
immune-related response assessment. While some differ-
ences were noted between the two criteria in 3 of the nine
patients with new lesions (the difference was in the number
of new lesions allowed in one patient, in the measurabilityof a new lymph node in one patient, and in the measure-
ment of a new lymph node in another patient), no differ-
ence was noted in best response assessment and TTP in
these 9 patients by two criteria. Since the appearance of
new lesion defines progression in RECIST, there is no
guideline as the how many new lesions are allowed by
RECIST. We based the upper limits of new lesions on
the number of target lesions allowed per organ and in
total by RECIST1.0 and 1.1, given that the original
irRC defines the limits of number of new lesions using
the limits for target lesions (up to 5 per organ, 5 cutane-
ous lesions and 10 visceral lesions) [5]. In the present
study, cutaneous lesions were counted toward in the total
number of target lesions.
We assessed interobserver agreement of the measure-
ments on baseline scans by two criteria, since the measure-
ment variability is an important factor when developing
and optimizing tumor response criteria. Interobserver
agreement of measurements was very high for both cri-
teria, with CCC above 0.98. The 95% limits of agreement
were very similar between the two criteria, (−23.0%,
14.1%) for irRC simulating RECIST1.0, and (−21.8%,
16.1%) for irRC simulating RECIST1.1. The result is some-
what different from the prior study of advanced NSCLC
patients, where measurements using RECIST1.1 was more
reproducible than measurements using RECIST1.0 [12].
The reason for the difference may be due to the difference
of the cohort with different tumor types, while the num-
ber of patients studied in each study is small to identify
definitive reasons. Nevertheless, it is reassuring that the
measurements with decreased number of lesions were as
reproducible as measurements with the original number of
lesions. More important observation is that the threshold
used to define response and progression, −30% and +20%,
was beyond the range of the 95% limits of agreement and
therefore can be considered to represent true change of
tumor burden rather than the measurement error [17,18].
The result provide supporting evidence of the cut-off values
used in RECIST, while one should note that 20% change for
progression can be within the upper limits depending on
the way we subtract one measurement from the other to
obtain difference (i.e., the 95% limits of (−23.0%, 14.1%) can
be (−14.1%, 23%) if measurement 1 was subtracted from
measurement 1 in the method). This is also consistent
with the prior studies of measurement variability, which
described the risk of misclassifying patients as progressors
[17-19]. However, such risk of misclassification for pro-
gression is probably less in irRC since it requires confirm-
ation on two consecutive scans for progression, which is
not required by RECIST [5,9-11].
The limitations of the study include retrospective design
with a cohort of patients treated at a single institution. The
results of the study can be validated in a larger multicenter
cohort of melanoma patients treated with immunotherapy.
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gate the association between response assessment by irRC
and overall survival, to find out which of the criteria most
accurately predicts survival. While either of two criteria
compared in the study were not fully established as guide-
line to assess immune-response, we defined the details of
the two criteria based on RECIST1.0 and RECIST1.1 while
keeping the important novel features of irRC published in
2009. Each of the criteria details used in the study has its
own rationale as described in the Method and Discussion,
and made by consensus of experienced oncoradiologists
who have focused on tumor response assessment. The
results of the study should be interpreted in the context of
the study design.Conclusions
In conclusion, reducing the number of target lesions
did not significantly affect the results of immune-related
response assessment or the measurement reproducibility
in advanced melanoma patients treated with ipilimumab.
These results are indicative that utilize up to 2 per organ
and 5 in total target lesions may be sufficient for
immune-related response assessment, as long as the
important features of irRC such as confirmation of
progression and inclusion of new lesion measurements
are kept, while these observations need to be validated in
a larger trial. Decreasing the number of target lesions may
help to increase the practicality of immune-related response
assessment, and help to make irRC more widely applicable
and adoptable for radiologists who are primarily using
RECIST 1.1 criteria.Methods
Patients
The study population consisted of 90 patients (53 males,
37 females; median age 62, range 25–87 years) with
advanced melanoma treated with ipilimumab at the
Dana-Farber Cancer Institute in two prospective clin-
ical trials, whose prospective tumor measurement
records during trials are available for review. Seventy-
five patients were treated in a phase 2, multicenter
treatment protocol for expanded access of ipilimumab
(BMS-734016) monotherapy in subjects with histologically
confirmed unresectable stage III or stage IV melanoma,
and 15 patients were treated in a phase 1 trial of Anti-
Cytotoxic T-Lymphocyte-Associated Antigen-4 (anti-
CTLA-4) Humanized Monoclonal Antibody (ipilimumab)
[20,21]. Fourteen patients in the phase II trial received a
dose of 10 mg/kg of ipilimumab, while the remaining 76
patients received a dose of 3 mg/kg. The protocols were
approved by the Dana-Farber/Harvard Cancer Center in-
stitutional review board, and all patients provided written
informed consent.Tumor response assessment
The original tumor measurements were performed
prospectively during the trial by staff radiologists at
Dana-Farber Cancer Institute at the baseline and at
every follow-up computed tomography (CT) examinations,
allowing up to 5 lesions per organ, and up to 10 lesions
in total according to RECIST1.0 [9]. CT scans were per-
formed at every 12 weeks in principle, while shorter inter-
val follow-up (i.e., 4 weeks) were performed if necessary
for the purposes such as confirmation of response or pro-
gression [8]. The tumor measurement records included
the number of the treatment cycle, date of assessment,
imaging modality, target lesion description and bidimen-
sional measurements, descriptions of nontarget lesions, the
presence or absence of new lesions with measurements if
present.
The original tumor measurement records completed in
the trials were retrospectively reviewed by a board-certified
radiologist (M.N.) with 8 years of experience in oncologic
imaging, and two sets of immune-related tumor response
assessments were performed (Table 2). The first assessment
utilized irRC simulating RECIST1.0, allows up to 5 lesions
per organ, up to 10 lesions for target lesions. The longest
diameter measurements were used for all target lesions.
The longest diameters of new lesions, if any, were also
included in the measurements, since this is one of the
important characteristics of irRC. Up to 5 new lesions
per organ, up to 10 new lesions were allowed. The sum
of the longest diameters of all target lesions (and new
lesions, if any) was calculated at baseline and each
follow-up study.
The second set of assessment utilized irRC simulating
RECIST1.1, which included the revised guidelines for
the number of target lesions and the measurement of
lymph nodes described in RECIST1.1 [10] (Table 2). The
criteria allowed up to 2 lesions per organ and up to 5
lesions in total, and required at least 15 mm in short axis
for lymph nodes to be measurable [10]. In this assessment
by irRC simulating RECIST1.1, when the number of target
lesions exceeded the limits (up to 2 per organ and 5 in
total), larger lesions based on the unidimensional measure-
ments (the longest diameter for non-nodal lesions and the
short axis for lymph nodes) were selected to remain as tar-
get lesions. Lymph nodes less than 15 mm in the short axis
were excluded from target lesions. The short-axis measure-
ments were used for lymph nodes instead of the longest
diameters [11]. Up to 2 new lesions per organ, up to 5 new
lesions in total were allowed, and the measurements of new
lesions were included in the sum of the measurements.
New lymph nodes have to be ≥15 mm in short axis to
be measurable, and the short axis measurements were
included in the sum for new nodes. Although the second
assessment utilized irRC simulating RECIST1.1, new lesion
by FDG-PET was not included in the response assessment
Table 2 Summary of measurement approaches for two assessments
irRC simulating RECIST1.0 irRC simulating RECIST1.1
Number of target lesions Up to 5 per organ, up to 10 in total Up to 2 per organ, up to 5 in total
Measurable lesions ≥10 mm in the longest diameter for all lesions ≥10 mm in the longest diameter for all lesions
except for lymph nodes
≥15 mm in short axis for nodes
Measurement of each lesion The longest diameter for all target lesions The longest diameter for non-nodal lesions, short
axis for lymph nodes
New lesions The presence of new lesion does not define progression Same as irRC simulating RECIST1.0 except:
The measurements of the new lesion (s) are included in
the sum of the measurements
A lymph node has to be ≥15 mm in short axis to
be a measurable new lesion and its short axis
measurement is included in the sum
Up to 5 new lesions per organ, up to 10 new lesions in
total can be added to measurements
Up to 2 new lesions per organ, up to 5 new lesions
in total can be added to the measurements
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irRC [5]. Absolute ≥5 mm increase (in addition to ≥20%)
for progression by RECIST1.1 was not used, because 1)
the main purpose was to evaluate the impact of reducing
the number of target lesions, and 2) the 5 mm require-
ment affected only a minority of patients in our prior
study of advanced NSCLC patients [13].
The sum of the measurements of target lesions (and
new lesions, if any) at baseline and each follow-up study,
and the percent changes at each follow-up were calculated
for the two sets of assessments. Response assessment was
assigned at each follow-up using the cut-off values for per-
cent changes used in RECIST1.0 and 1.1 (≥20% increase
for disease progression (PD), ≥30% decrease for partial re-
sponse (PR)), since both assessments used unidimensional
measurements as in RECIST [9-11]. Complete response
(CR) required disappearance of all lesions including lymph
nodes for irRC simulating RECIST1.0, while all lymph
nodes must be < 10 mm short axis by irRC simulating
RECIST 1.1 [9-11]. Confirmation by two consecutive ob-
servations not less than 4 weeks apart was required for
irCR, irPR and irPD, since it is one of the most important
features of the original irRC to capture immune-related
response [5]. Best overall response was assigned to each
patient using the two criteria. Best overall response is the
best response recorded from the start of the study
treatment until the end of treatment or the last follow-up,
taking into account any requirement for confirmation.
Measurement variability
To assess variability of measurements, a board-certified
radiologist (M.N.) performed tumor measurements of
target lesions on baseline scans in a randomly selected
30 patients. The prospective baseline tumor measure-
ments during trials in these patients were performed
by staff radiologists at our institution other than the radi-
ologist (M.N.). The radiologist performed measurements
of the target lesions that have been already selected duringtrials. Tumor table templates indicating the location, de-
scription, and series and image numbers of target lesions
(such as “right lower lobe lung lesion, series 3, image 30”)
were provided to the radiologist, who was not allowed
to access the original measurements during the trials.
Measurements were performed using a measurement
tool on a picture archiving communication system (PACS)
workstation (Centricity, GE Healthcare), which was also
used for measurements during the trials. The sum of the
longest diameters of all target lesions was recorded for the
measurements by irRC simulating RECIST1.0. The mea-
surements by irRC simulating RECIST1.1included the
lesions that remained as target after applying revised
guidelines for the number of lesions and lymph node
measurability, and the sum of the longest diameters of
non-nodal target lesions and the short axis measurements
of target lymph nodes were recorded.
Statistical analysis
The number of target lesions by two assessments was
compared using a Wilcoxon signed rank test. The baseline
measurements and the percentage changes at each follow-
up by two assessments were compared using Spearman
correlation. A weighted kappa analysis was performed to
assess the level of agreement between responses by the two
assessments using Fleiss-Cohen quadratic weights [13].
Agreement between the two assessments was categorized
as poor (weighted κ < 0), slight (weighted κ = 0–0.20), fair
(weighted κ = 0.21–0.40), moderate (weighted κ =0.41–
0.60), substantial (weighted κ = 0.61–0.80), and almost per-
fect (weighted κ > 0.80) [12,13]. Time to progression (TTP)
according to two measurement records was estimated using
the Kaplan-Meier method [22].
Interobserver variability was assessed using CCCs,
mean relative difference (%), and 95% limits of agree-
ment (%), for the measurement using irRC simulating
RECIST 1.0 and the measurements using irRC simulating
RECIST1.1. CCC was used to assess reproducibility of two
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two measurements have mean u1 and u2, with variance σ21; σ
2
2;
and covariance σ12;CCC ¼ 2 σ12ð Þ= σ21 þ σ22;þ; ðu1u2Þ2
 
.
CCCs are com- posed of a measure of precision (how far
each pair of measurements deviates from the best-fit line
through the data) and a measure of accuracy (the distance
between the best-fit line and the 45 line through the
origin). A value of 1 indicates perfect agreement and −1
indicates perfect reversed agreement [23]. Bland-Altman
plots were used to demonstrate agreement in the two
measurements, with 95% limits of agreement and the
average relative difference, computing the mean rela-
tive difference (%) between the two measurements
(100*[M1-M2]/M1; M1 =Measurements during trial, M2 =
Measurements by the radiologist in this study) [18].
All p values are based on a two-sided hypothesis. A
p value of less than 0.05 was considered to be significant.
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